238 related articles for article (PubMed ID: 28641522)
1. Advances on PPARγ Research in the Emerging Era of Precision Medicine.
Lu P; Zhao Z
Curr Drug Targets; 2018; 19(6):663-673. PubMed ID: 28641522
[TBL] [Abstract][Full Text] [Related]
2. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
3. PPARγ ligands and their therapeutic applications: a patent review (2008 - 2014).
Takada I; Makishima M
Expert Opin Ther Pat; 2015 Feb; 25(2):175-91. PubMed ID: 25416646
[TBL] [Abstract][Full Text] [Related]
4. PPARγ signaling and emerging opportunities for improved therapeutics.
Wang S; Dougherty EJ; Danner RL
Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
[TBL] [Abstract][Full Text] [Related]
5. PPARγ signaling and metabolism: the good, the bad and the future.
Ahmadian M; Suh JM; Hah N; Liddle C; Atkins AR; Downes M; Evans RM
Nat Med; 2013 May; 19(5):557-66. PubMed ID: 23652116
[TBL] [Abstract][Full Text] [Related]
6. The Potential Roles of Post-Translational Modifications of PPARγ in Treating Diabetes.
Ji X; Zhang W; Yin L; Shi Z; Luan J; Chen L; Liu L
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551260
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
8. In silico approach for the discovery of new PPARγ modulators among plant-derived polyphenols.
Encinar JA; Fernández-Ballester G; Galiano-Ibarra V; Micol V
Drug Des Devel Ther; 2015; 9():5877-95. PubMed ID: 26604687
[TBL] [Abstract][Full Text] [Related]
9. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Wang M; Tafuri S
J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.
Ferroni P; Della-Morte D; Pileggi A; Riondino S; Rundek T; Ricordi C; Guadagni F
Curr Vasc Pharmacol; 2013 May; 11(3):338-51. PubMed ID: 23650948
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
12. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones and PPARγ agonists: time for a reassessment.
Cariou B; Charbonnel B; Staels B
Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
[TBL] [Abstract][Full Text] [Related]
14. Natural Peroxisome Proliferator-Activated Receptor γ (PPARγ) Activators for Diabetes.
Abdallah HM; El Dine RS; Mohamed GA; Ibrahim SRM; Shehata IA; El-Halawany AM
Altern Ther Health Med; 2020 Jul; 26(S2):28-44. PubMed ID: 31221946
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
16. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
Higgins LS; Depaoli AM
Am J Clin Nutr; 2010 Jan; 91(1):267S-272S. PubMed ID: 19906796
[TBL] [Abstract][Full Text] [Related]
17. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
Dubois M; Vantyghem MC; Schoonjans K; Pattou F
Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):511-23. PubMed ID: 12527853
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.
Karalliedde J; Buckingham RE
Drug Saf; 2007; 30(9):741-53. PubMed ID: 17722967
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones as antidiabetic agents: A critical review.
Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
[TBL] [Abstract][Full Text] [Related]
20. Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.
Karak M; Bal NC; Bal C; Sharon A
Curr Diabetes Rev; 2013 Jul; 9(4):275-85. PubMed ID: 23746081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
